Terug
naar lijst
- Auteur
- NVMO-commissie BOM
- Printdatum
- 14-09-2012
- E-pubdatum
- 14-09-2012
- Bron
- Medische Oncologie
Pemetrexed als onderhoudsbehandeling bij stadium IIIB/IV niet-kleincellig longcarcinoom
Op basis van de twee besproken fase III-studies kan worden geconcludeerd dat onderhoudsbehandeling met pemetrexed, toegepast na inductiebehandeling bij patiënten met een nietplanocellulair gemetastaseerd longcarcinoom (stadium IIIB/ IV), de PFS en OS significant en in klinisch relevante mate verlengt.
Referenties
- Soon YY, Stockler ML, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27(20):3277-83.
- Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374(9699):1432-40.
- Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012;13(3):292-9.
- Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-smallcell lung cancer. J Clin Oncol 2008;26(21):3543-51.
- Paz Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13(3):247-55.
- Paz Ares L, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(18) (suppl; abstr LBA7507).